29.28

1.25% -0.37

After Hours: 29.28

Mineralys Therapeutics Inc (MLYS)

Overview News Price History Option Chain Financials Discussions Forecast

Mineralys Therapeutics Inc stock is traded at $29.28, with a volume of 821.75K. It is down -1.25% in the last 24 hours and up +8.57% over the past month. Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Previous Close:

$29.65

Open:

$30

24h Volume:

821.75K

Relative Volume:

0.68

Market Cap:

$2.41B

Revenue:

Net Income/Loss:

$-154.65M

P/E Ratio:

-12.31

EPS:

-2.3786

Net Cash Flow:

$-142.43M

1W Performance:

+13.09%

1M Performance:

+8.57%

6M Performance:

-26.15%

1Y Performance:

+87.33%

1-Day Range:

$28.47

$30.86

1-Week Range:

$25.16

$30.86

52-Week Range:

$12.59

$47.65

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name

Mineralys Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(888) 378-6240

Address

150 N. RADNOR CHESTER RD., RADNOR

Employee

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

MLYS's Discussions on Twitter

Compare MLYS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLYS Mineralys Therapeutics Inc	29.28	2.44B	0	-154.65M	-142.43M	-2.3786
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-26	Initiated	TD Cowen	Buy
Jun-11-25	Initiated	Jefferies	Hold
Jul-10-24	Initiated	H.C. Wainwright	Buy
Apr-02-24	Initiated	Goldman	Buy
Mar-07-23	Initiated	BofA Securities	Buy
Mar-07-23	Initiated	Credit Suisse	Outperform
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Guggenheim	Buy
Mar-07-23	Initiated	Stifel	Buy
Mar-07-23	Initiated	Wells Fargo	Overweight

View All

Mineralys Therapeutics Inc Stock (MLYS) Latest News

May 05, 2026

Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

May 05, 2026

Two new Mineralys hires get stock options and RSUs under Nasdaq rule - Stock Titan

May 05, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 05, 2026

Mineralys to Report First-Quarter Results on May 6 - MyChesCo

May 05, 2026

Mineralys Therapeutics Advances Drug Commercialization Through Comprehensive Contract Support - Faegre Drinker

May 05, 2026

Mineralys fireside chat at Bank of America conference streams May 12 - Stock Titan

May 05, 2026

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference - marketscreener.com

May 05, 2026

May 03, 2026

Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now? - Insider Monkey

May 03, 2026

(MLYS) Volatility Zones as Tactical Triggers - Stock Traders Daily

May 03, 2026

May 02, 2026

Mineralys Therapeutics (MLYS) Projected to Post Earnings on Wednesday - MarketBeat

May 02, 2026

May 01, 2026

Mineralys Therapeutics (NASDAQ:MLYS) Trading 8.2% HigherShould You Buy? - MarketBeat

May 01, 2026

Why Mineralys Therapeutics Stock Is Surging Today - TipRanks

May 01, 2026